Digital Content 
NEWS #PharmaBuzz
13 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/13/3165267/0/en/HUTCHMED-Highlights-FRUSICA-2-Registration-Trial-Data-to-be-Presented-at-the-2025-ESMO-Congress.html
01 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html
06 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/04/3094067/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NDA-Acceptance-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-the-Treatment-of-Advanced-Renal-Cell-Carcinoma.html
18 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2025/03/19/3045072/0/en/HUTCHMED-and-Innovent-Jointly-Announce-that-the-FRUSICA-2-Phase-II-III-Study-of-Fruquintinib-and-Sintilimab-Combination-Has-Met-its-Primary-Endpoint-in-Advanced-Renal-Cell-Carcinom.html
18 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/innovent-and-hutchmed-jointly-announce-that-the-frusica-2-phase-23-study-of-sintilimab-and-fruquintinib-combination-has-met-its-primary-endpoint-in-advanced-renal-cell-carcinoma-in-china-302405211.html
03 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/03/2990362/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NMPA-Conditional-Approval-for-ELUNATE-Fruquintinib-in-Combination-with-TYVYT-Sintilimab-Injection-for-the-Treatment-of-Advanced-Endometrial-C.html
Share 